幽门螺杆菌相关性消化性溃疡3种治疗方案的比较

目的评估幽门螺杆菌（HP）相关性消化性溃疡3种治疗方案的临床疗效。方法采用随机平行对照临床研究方法，将120例HP相关性消化性溃疡患者随机均分为3组。治疗第1周，3组均给予HP根除三联方案；第2—6周，A组口服国产雷贝拉唑（瑞波特，每次10mg，每天1次），B组口服瑞巴派特组予瑞巴派特（膜固思达，每次100mg，每天3次），C组口服雷贝拉唑（每次10mg，每天1次）联合瑞巴派特（100mg／次，每天3次）。结果疗程结束后3组临床症状均有显著性改善，A组、C组比B组显著（P〈0．05）；第6周末复查胃镜，镜下黏膜情况差异无统计学意义，B组、C组组织学炎症消退均比A组明显。结论治疗HP相关性消化性溃疡，雷贝拉唑联合瑞巴派特比两药单用能更好地缓解临床症状、促进炎症消退，溃疡愈合质量更高。

Clinical Study on Different Therapies of Helicobecter Pylori-Related Peptic Ulcer

Objective To evaluate the efficacy of three kinds of therapy in treating active peptic ulcer with Helicobacter（H. ） pylori- positive detected by the rapid urease test. Methods A randomized, parallel-controlled clinical study was conducted. 120 patients were randomly divided into the group A （n=40）,the group B （n=40） and the group C （n=40）. In the first week, the three groups received H. pylori three- drug eradication regimen. In the second to sixth week, the group A was given rabeprazole 10 mg once a day, the group B was given rebamipide 100 mg three times a day, and the group C was given rabeprazole 10 mg once a day with rebamipide 100 mg three times a day. Results Among all the groups, the reductions of clinical symptoms, such as abdominal pain, abdominal distension, acid reflux and belching were significant. The group A and C were more effective than the group B respectively. There was no significant difference among the three groups in reducing severity of mucosa inflammation by endoscopy. Obvious inflammatory cells withdrawal was observed in the group B and C at the end of six week. Conclusion In treating Helicobecter pylori- related active peptic ulcer, the treatment of rabeprazole combined with rebamipide may effectively relieve the dyspeptic symptoms, improve the mucosa inflammation and the quality of ulcer healing as well than using anyone alone.